Varian Vitesse Brachytherapy Systems Treatment Planning FDA Approval

January 28, 2013 — Varian Medical Systems has received a U.S. Food and Drug Administration (FDA)- 510(k) clearance for the latest version of its Vitesse real time planning for HDR brachytherapy which is used to plan and perform high-dose-rate (HDR), ultrasound-guided brachytherapy treatments for prostate cancer.

"This version of Vitesse reduces the number and complexity of steps involved in planning and completing a treatment. It eliminates the need for a data transfer to another software program, and avoids moving the patient to a CT scanner for images in the middle of the procedure. For these reasons, most clinicians will see a reduction in the amount of time needed to complete these treatments, often by as much as an hour and a half," said Tim Clark, marketing manager for Varian BrachyTherapy.

HDR brachytherapy involves delivering radiotherapy from inside the body by temporarily placing a tiny radioactive source directly into the tumor or other targeted area. Using a robotic device called an afterloader, clinicians place the radioactive source into positions through needles that have been inserted into the area being treated. The source is then moved within the needles under computer control to create the specified dose distribution within the patient's anatomy.

Using the latest version of Vitesse, HDR brachytherapy treatment plans can be created in a real-time environment, using ultrasound images generated in the operating room rather than computed tomography (CT) scans generated elsewhere. This avoids the need to move the patient to a CT scanner room for imaging after the needles have been put in place. The process can now be completed entirely within the Vitesse program, from capturing the ultrasound image to finalizing an approved treatment plan.

In addition to receiving FDA 510(k) clearance, which permits sale of the Vitesse software in the United States, Varian has also obtained the CE mark which permits sales in the European Union and other countries where the CE mark is recognized.

For more information: www.varian.com


Related Content

News | Radiation Therapy

April 18, 2024 — Accuray Incorporated announced that as part of its commitment to advancing patient care the company has ...

Time April 18, 2024
arrow
News | FDA

February 15, 2024 — Merit Medical Systems, Inc., a global leader of healthcare technology, has received US Food and Drug ...

Time February 15, 2024
arrow
News | Radiation Oncology

February 12, 2024 — Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its ...

Time February 12, 2024
arrow
News | Radiology Business

February 1, 2024 — Theragenics Corporation, a global leader in minimally invasive brachytherapy, interventional devices ...

Time February 01, 2024
arrow
News | Radiology Business

October 9, 2023 — CIVCO Radiotherapy and Qfix announced the launch of a new brand, CQ Medical. This brand reflects the ...

Time October 09, 2023
arrow
News | Women's Health

October 1, 2023 — People who engage in sexual activity or vaginal dilation after chemoradiation treatment for cervical ...

Time October 01, 2023
arrow
News | Radiation Oncology

September 13, 2023 — Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients ...

Time September 13, 2023
arrow
News | Radiation Oncology

September 12, 2023 — Michael J. Zelefsky, MD, a renowned leader in radiation oncology, is joining NYU Langone’s ...

Time September 12, 2023
arrow
News | Proton Therapy

July 5, 2023 — RaySearch Laboratories AB announced a strategic collaboration agreement with B dot Medical Inc. aimed at ...

Time July 05, 2023
arrow
News | Radiation Oncology

May 31, 2023 — Elekta announced the launch of the first phase of Elekta ONE*, its most comprehensive and advanced ...

Time May 31, 2023
arrow
Subscribe Now